Leo Pharma España company information, Employees & Contact Information

LEO Pharma Delivers 7% Revenue Growth at CER in H1 2025 and Achieves Key Milestones Enabling Future Growth Business Wire

LEO Pharma secures rights to Boehringer’s Spevigo for $105m Pharmaceutical Technology

Leo Pharma's slow response to app lapse scolded by UK marketing watchdog Fierce Pharma

LEO Pharma Topical Cream Is Now the First FDA-Approved Drug for Chronic Hand Eczema MedCity News

Leo Pharma is one step closer to its 2025-goal – CEO sees no obstacles on the road to the stock market medwatch.com

Dermatitis data: LEO Pharma, Corvus candidates progress FirstWord Pharma

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront PMLiVE

LEO Pharma Adds Skin Drug from Boehringer as It Readies for IPO Bloomberg

Gilead, LEO Pharma partner to develop programs for inflammatory diseases Reuters

Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma Fierce Biotech

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases Dermatology Times

Gilead and LEO Pharma partner to develop oral STAT6 program PharmaTimes

Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema Fierce Pharma

Leo Pharma boss on new HR director: "Hard to overestimate the importance of the task" medwatch.com

Junshi to partner LEO Pharma for toripalimab distribution Pharmaceutical Technology

LEO Pharma and the Parker Institute join forces to advance dermatology research PMLiVE

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases Business Wire

Leo Pharma maintains IPO pursuit medwatch.com

Leo Pharma finds derms want better chronic hand eczema meds Fierce Pharma

Leo Pharma CEO has fallen for Denmark: Considering settling permanently medwatch.com

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab PMLiVE

LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth Via Ritzau

LEO Pharma Announces Health Canada Approval of Anzupgo® for Treatment of Moderate to Severe Chronic Hand Eczema PR Newswire Canada

LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema PMLiVE

LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial Clinical Trials Arena

Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16% Business Wire

FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema National Eczema Association

Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign Fierce Pharma

LEO Pharma to market Junshi's PD-1 inhibitor Loqtorzi in Europe FirstWord Pharma

LEO Pharma delivers 7% revenue growth in 1st-half 2025 The Pharma Letter

Leo Pharma unveils up to 250 layoffs and relocations amid CEO's revamp Fierce Pharma

LEO Pharma's Delgocitinib Launches for Chronic Hand Eczema in Germany Dermatology Times

Kyowa Kirin and LEO Pharma terminate collaboration on Dovobet | Pharmaceutical | The Pharmaletter The Pharma Letter

Leo Pharma CEO: Phone ringing off the hook since big deals with Gilead and Boehringer medwatch.com

After transformation under new CEO, Leo Pharma touts innovation model and financial progress Fierce Pharma

New management team in Leo Pharma: Two directors let go and a new hired from Novo Nordisk medwatch.com

Leo Pharma enters partnership with Belgian AI company medwatch.com

Leo Pharma receives US approval for “growth driver” eczema treatment medwatch.com

Leo Pharma will stay calm after acquisition and approval: "Don't expect news like this every two weeks" medwatch.com

Leo Pharma to move production and cut 100 jobs at headquarters medwatch.com

Leo Pharma CSO comments on closure of research department after its new agreement with contract researchers medwatch.com

Leo Pharma's topical JAK drug posts phase 3 win in chronic hand eczema Fierce Pharma

More layoffs at Leo Pharma: 200 jobs to be cut medwatch.com

Leo Pharma meets big 2023 goal but substantial deficit remains medwatch.com

ICON and LEO Pharma join forces on clinical trial mission PharmaTimes

Investor on Leo Pharma's new acquisition: "It's not like the market is thinking wow" medwatch.com

Leo Pharma Announces Positive Results for Delgocitinib Cream for Chronic Hand Eczema Managed Healthcare Executive

Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off Fierce Pharma

Leo Pharma secures another approval for key growth hope medwatch.com

Leo Pharma CEO hungry for acquisitions after Gilead deal medwatch.com

Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme Fierce Biotech

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis Pharmafile

Former Novo Nordisk manager to sharpen focus at Leo Pharma: "We can't do everything at once" medwatch.com

Leo Pharma hires head of IR ahead of possible IPO medwatch.com

Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron's formidable Dupixent? Fierce Pharma

LEO Foundation and Nordic Capital Partner up to Further Strengthen LEO Pharma’s Leading Position in Medical Dermatology Business Wire

Boehringer Ingelheim on sale to Leo Pharma: It's about priorities medwatch.com

Leo Pharma's growth hope receives approval in the UK medwatch.com

Vianex to start producing meds for Leo Pharma eKathimerini.com

Leo Pharma signs multi-million-euro deal with Boehringer Ingelheim: Acquires rights to psoriasis drug medwatch.com

Despite new layoffs: Leo Pharma CEO does not rule out further measures medwatch.com

Leo Pharma will not use acquisition option after candidate disappoints in phase III trial medwatch.com

Leo Pharma to terminate up to 150 R&D jobs medwatch.com

Leo Pharma, Glenmark Settle Enstilar Psoriasis Drug Patent Suit Bloomberg Law News

STADA expands its business with the acquisition of FITO from LEO Pharma intlbm

Leo Pharma pens Oneness Biotech, Microbio Shanghai pact for skin and asthma drug Fierce Biotech

Ex-Sanofi executive to head up translational medicine at LEO Pharma Fierce Biotech

Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline" medwatch.com

LEO Pharma taps delivery specialist Elektrofi for subQ dermatology antibodies Fierce Pharma

Leo Pharma appoints new General Counsel medwatch.com

Leo Pharma to withdraw from a quarter of its markets medwatch.com

Bayer to sell prescription dermatology unit and transfer 450 employees to Leo Pharma Fierce Pharma

Leo Pharma introduces bonus program for employees medwatch.com

LEO Pharma gears for growth with senior leadership changes Via Ritzau

AstraZeneca sells two dermatology drug rights to LEO Pharma Reuters

Danish Leo Pharma is Launching an Innovation Lab in Israel CTech

LEO Pharma Buys Astellas’ Dermatology Business for $725M Genetic Engineering and Biotechnology News

STADA acquires FITO from LEO Pharma and expands consumer healthcare in the MENA region ZAWYA

LEO Pharma to release clinical trial data Pharmafile